Developmental Venous Anomaly: Its Impact on Brain Parenchymal Function as Revealed by FDG PET.

Developmental venous anomaly (DVA) is a common benign brain vascular malformation, typically asymptomatic, with intervention required when complications arise. We present the case of a 63-year-old man with mild cognitive decline whose brain FDG PET showed decreased uptake not only at the site of DVA, but in the extended surrounding parenchyma where MRI showed no parenchymal abnormalities. DVAs arise from developmental irregularities in the embryonic venous system, but likely affecting a greater extent of the surrounding parenchymal functions.

Unveiling dynamic hepatocyte plasticity in HepaRG cells with a dual CYP reporter system.

Primary hepatocytes are widely utilized for investigating drug efficacy and toxicity, yet variations between batches and limited proliferation capacity present significant challenges. HepaRG cells are versatile cells, capable of maintaining an undifferentiated state and differentiating through dimethyl sulfoxide treatment, allowing for molecular analysis of hepatocyte plasticity. To elucidate the underlying molecular mechanisms of HepaRG cell plasticity, we used CYP3A4G/7R HepaRG cells engineered to express DsRed under the control of the fetus-specific CYP3A7 gene and EGFP under the adult-specific CYP3A4 gene promoter.

[Evaluation of the Stability and Antibacterial Activity of Burow's and Neo-Burow's Solutions was Prepared Using Different Methods].

Burow's solution is a 13% aluminum acetate solution used for treating chronic suppurative otitis media. However, multiple formulations for Burow's and neo-Burow's solutions are used as in-hospital preparations. Each formulation uses different types and amounts of reagents, and takes a different time to prepare.